Jubilant Pharmova Limited has appointed Daniel J. O’Connor as the new Chief Executive Officer of its proprietary novel drugs business, Jubilant Therapeutics Inc. This leadership transition is aimed at accelerating the company's innovation-led growth strategy in the biotech and oncology space.
Company Information
Company
Jubilant Therapeutics
Location
Yardley, Pennsylvania, United States
About
Jubilant Therapeutics is a patient-focused biopharmaceutical company advancing potent and selective small molecule modulators to address specific unmet medical needs in oncology and autoimmune diseases. The company’s leadership and scientific team are science-driven executives with global pharma background and experience in advancing innovative drug candidates into the clinic. Jubilant Therapeutics is headquartered in the U.S. with independent board and management, guided by globally renowned KOLs and SAB.
Fundz sees it the moment Jubilant Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
YardleyManufacturingBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma